Breekveldt, Emilie C. H.
Toes-Zoutendijk, Esther
de Jonge, Lucie
Spaander, Manon C. W.
Dekker, Evelien
van Kemenade, Folkert J.
van Vuuren, Anneke J.
Ramakers, Christian R. B.
Nagtegaal, Iris D.
van Leerdam, Monique E.
Lansdorp-Vogelaar, Iris
Article History
Received: 29 November 2022
Accepted: 7 February 2023
First Online: 22 February 2023
Declarations
:
: This study was approved by the Ministry of Health, Welfare and Sport on advice of the Dutch Health Council and falls under the Population Screening Act (WBO). The WBO monitors all screenings and not only those of the National Population Screening Programme. If the permit is issued, it means that the screening is scientifically sound, that it is in accordance with legal rules for medical treatment and that the expected efficacy of the population screening outweighs the risks to health. The Population Screening Act has its own system of protection [CitationRef removed]. Furthermore, the conditions under which care may be provided within the Netherlands also apply to public health and include the following legislation: the Medical Treatment Agreement Act (WGBO), the Individual Health Professions Act (Wet BIG) and the General Data Protection Regulation (AVG) [CitationRef removed]. The study will be carried out in accordance with relevant guidelines and regulations. Written informed consent will be obtained from every participant.
: Not applicable.
: The authors declare that they have no competing interests.
: Issue date: July 16th, 2021.Protocol Amendment Number: 02.Author(s): ECHB, ETZ, ILV.Revision Chronology: July 16th, 2021: original; January 28th, 2022: 1st amendment (Primary reason for amendment: alteration of 3-year intervention group (category changed from 0–2.6 µg Hb/g feces to 0 µg Hb/g feces).
: See Additional fileInternalRef removed: Table 3.
: The study results will be released and will be publicly available to the participants, involved organizations, public health officials and the general medical community.